SCHEMBL3222825

SCHEMBL3222825

CN1CCN(c2ccccc2)c2ccc(Br)cc2C1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 1/20 0.40
MAOA P21397 2/20 0.39
MAOB P27338 2/20 0.39
HSD17B3 P37058 3/20 0.38
SRD5A1 P18405 1/20 0.38
ADRA2C P18825 2/20 0.37
KMT2A Q03164 2/20 0.36
LMNA P02545 1/20 0.36
POLB P06746 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HTR6 P50406 1/20 0.36
SIGMAR1 Q99720 1/20 0.36
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
BRD2 P25440 1/20 0.36
ASIC3 Q9UHC3 1/20 0.36
HRH4 Q9H3N8 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3223749 0.86 POLB (0.42) SCN9ASRD5A1KMT2APOLBHTR6
SCHEMBL3236889 0.86 ALDH1A1 (0.42) SCN9ASRD5A1KMT2ALMNASMN1; SMN2
SCHEMBL3227778 0.85 HTR3A (0.51) SCN9AHTR6SIGMAR1NPC1RAB9A
SCHEMBL3235658 0.84 SLC6A2 (0.43) SCN9AMAOAMAOBSRD5A1ADRA2C
SCHEMBL3479627 0.83 ALDH1A1 (0.39) SCN9AHSD17B3SRD5A1HTR6HRH4
SCHEMBL3236291 0.82 DRD1 (0.48) SCN9A
SCHEMBL3224341 0.82 POLB (0.48) SCN9AMAOAMAOBHSD17B3SRD5A1
SCHEMBL3238745 0.82 ALDH1A1 (0.48) SCN9AMAOAMAOBADRA2CKMT2A
SCHEMBL3479777 0.82 ADRA2C (0.51) SCN9AADRA2CKMT2AHTR6SIGMAR1
SCHEMBL3232204 0.81 MAOA (0.50) MAOAMAOBADRA2CKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096546-B2 Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2015-08-04 US disclosed
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ALBANY MOLECULAR RESEARCH, INC. (US) 2010-06-03 US disclosed
EP-2146722-A1 ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN AMR Technology, Inc. (US) 2010-01-27 EP disclosed
WO-2008141081-A1 ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN AMR TECHNOLOGY, INC. (US) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ADRA1B, ADRB1, ADRA1D SCN9A 795/4885MAOA 68/4885MAOB 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.